Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls BioSpaceThe Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.Clinical DataOncologyRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) BioSpace The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer. Clinical DataOncologyRead full story Post navigation Previous: Jazz and Lilly cancer drugs cleared for use by NHSNext: MSD, Eisai report setback in first-line kidney cancer trial Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
